Table 1. Systematic reviews: discontinuation rates in placebo arms of randomized trials owing to adverse events.

Reference	Verum	Number of studies	Discontinuation rate (%)
e9	Primary and secondary prevention of cardiovascular diseases: statins	20	4–26*
e10	Multiple sclerosis: immune modulators	56	2.1 (95% CI: 1.6–2.7)
e10	Multiple sclerosis: symptomatic treatment	44	2.4 (95% CI: 1.5–3.3)
e11	Acute treatment of migraine	59	0.3 (95% CI: 0.2–0.5)
e11	Prevention of migraine	31	4.8 (95% CI: 3.3–6.5)
e11	Prevention of tension headache	4	5.4 (95% CI: 1.3–12.1)
22	Painful peripheral diabetic polyneuropathy	62	5.8 (95% CI: 5.1–6.6)
22	Fibromyalgia syndrome	58	9.5 (95% CI: 8.6–10.7)

CI = confidence interval;

^*no data on pooled discontinuation rates